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We would like to oﬀ  er some comments on the updated 
meta-analysis on intravenous magnesium sulphate for 
aneurysmal subarachnoid hemorrhage [1], which was 
conducted by Wong and colleagues and published in a 
recent issue of Critical Care.
First, the authors did not mention a (non-blinded) 
random  ized placebo-controlled trial conducted by 
Akdemir and colleagues and published in 2009 [2]. 
Although this study would probably not pass Wong and 
colleagues’ method of scrutiny, we believe that it should 
be mentioned alongside two other studies the authors 
described but did not include in the data analysis.
Second, the study by Westermaier and colleagues [3] 
should not be included in the data analysis. Th  ese 
authors, in contrast to those of the other included studies 
in which magnesium was used as an add-on therapy, did 
not use nimodipine in any of the included patients. Wong 
and colleagues exclude the study by Schmid-Elsaesser 
and colleagues [4] because nimodipine was not used in 
the magnesium group but omit doing the same for the 
study by Westermaier and colleagues.
Th  ird, Figure 3 [1] shows that the number of control 
subjects in ‘Veyna 2002’ was 20. However, in that study, 
the outcome data in the control group were present for 
only 16 patients (4 of the 20 patients were withdrawn 
because study requirements were not met) [5]. 
Accordingly, the risk ratios in Figure 3 should be adjusted.
Fourth, given Wong and colleagues’ deﬁ  nition  of 
delayed cerebral ischemia, we wonder why the studies of 
Veyna and colleagues [5], Muroi and colleagues [6], and 
their own study in 2006 [7] were not included in Figure 1 
[1]. In the study by Veyna and colleagues [5], the outcome 
measure ‘clinical vaso  spasm’ was deﬁ  ned as a ‘new focal 
neurological deﬁ  cit that could not be accounted for by 
other causes’. Although the time frame in which this was 
scored is not mentioned, this was during the patients’ 
stay in the intensive care unit and therefore would be 
clinically relevant to include in Figure 1 [1]. Th  e same 
applies to the outcome measures ‘delayed ischemic 
neurological deﬁ  cit’ in the study by Muroi and colleagues 
[6] and ‘symptomatic vasospasm’ in their own study in 
2006 [7].
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We thank Abdo and colleagues for their interest in our 
articles [1,8] and for their comments. We would like to 
oﬀ  er the following clariﬁ  cations.
First, it is unfortunate that the article by Akdemir and 
colleagues [2] slipped through the established search 
methodology for the journals. Nevertheless, the authors’ 
results on the lack of an eﬀ  ect of magnesium sulphate 
infusion on clinical outcome echoed the con  clusion of 
our review.
Second, the study by Schmid-Elsaesser and colleagues 
[4] compared magnesium sulphate infusion with nimodi-
pine, the latter of which has an established beneﬁ  cial 
eﬀ   ect on aneurysmal subarachnoid hemorrhage. Th  e 
study by Westermaier and colleagues [3] was trickier in 
mention  ing how their cohort of patients employed 
nimodi  pine in the Discussion section but not in the 
Results section. Westermaier and colleagues mentioned 
that they did not seek an alternative route of 
administration for oral tablet forms of nimodipine for 
intubated patients but did not mention that they would 
omit the nimodipine oral tablets in good-grade patients. 
Th   is actually is the policy in some neuro  surgical centers. 
Th  e nature of the comparison between magnesium 
sulphate infusion with placebo infusion is also diﬀ  erent 
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© 2011 BioMed Central Ltdfrom that of Schmid-Elsaesser and colleagues [4]. Again, 
the omission of the data of Westermaier and colleagues 
did not alter the conclusion of the review.
Th   ird, Veyna and colleagues [5] exposed a problem in 
the earlier study report format, in which numbers of 
patients were not mentioned in each step. Withdrawal 
could mean just the study medications, and the patients 
were assessed for intention-to-treat analysis. If the four 
control patients had been excluded, the result would have 
been the same (Figure 1) [5,6,9].
Fourth, the new deﬁ  nition of delayed cerebral ischemia 
included the subsets of patients with asymptomatic 
cerebral infarction [10], which turned out to be an 
important prognostic factor and which earlier studies 
ignored. Lastly, we would like to emphasize that the 
detrimental eﬀ  ect of higher-achieved plasma magnesium 
concentrations further supported the results of the 
current meta-analysis [11].
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Figure 1. Fixed-eff  ects model of risk ratio for a favorable outcome at 3 months. A comparison between magnesium sulphate infusion and a 
placebo in patients with aneurysmal subarachnoid hemorrhage is shown. CI, confi  dence interval; M-H, Mantel-Haenszel.
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